Sir -The updated Royal College of General Practitioner's study presented in the November issue (Key & Hannaford, 1988) shows results relevant to studies on the possible association between the pill and breast cancer in southern Sweden. In studying the tumour biology and prognosis among pill users versus others, we have already gathered the following results not citedoin their paper.
Early users of oral contraceptives (OCs) have larger primary breast tumours than later users and never users (Olsson et al., 1986 (Olsson et al., , 1987a ) and more often axillary metastases (Olsson et al., 1985b) . The finding in the RCGP study of a higher percentage with tumours of greater invasiveness among women aged 35 and younger at diagnosis who were ever users supports our results.
The oestrogen and progesterone receptor content are lower among early users versus later users, who themselves show lower levels than never users after adjusting for age at diagnosis (Olsson et al., 1988) . This implies more undifferentiated tumours among early users.
The survival of early OC-users is significantly poorer than later users and never users (Olsson et al., 1987b (Olsson et al., , 1988 , which also is in accord with findings of the RCGP study in women younger than 35 years at diagnosis. A number of studies have assessed the survival of ever users of OCs versus never users in premenopausal women (Spencer et al., 1978;  Royal College of General Practitioners, 1981; Matthews et at., 1 981; Vessey et al., 1983; Rosner et al., 1985a,b; Greenberg et al., 1985; Millard et al., 1987; Palshof, 1988) . In these studies in general no adverse effect of ever OC-use on survival have been detected. Using the same definition, the RCGP study and our study could not find a significant poorer survival in ever users versus never users for the whole patient material of premenopausal women (Kay & Hannaford, 1988; Olsson et al., 1988) . If OC-use increases the risk of breast cancer especially after early use, as our finding so far implies in southern Sweden (Olsson et al., 1985a ) the expectation therefore would be that the tumour biology and the prognosis would be adversely affected especially after early use, findings that so far seem to be true in our and in the RCGP study.
Further investigations especially addressing tumour biology and prognosis after early use should be given a high priority. Such studies may help us to better understand relevant biology of importance for the alleged association. 
